Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer In vitro Models.
| Title: | Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer In vitro Models. |
|---|---|
| Authors: | Janev A; Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.; Ramuta TŽ; Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.; Tratnjek L; Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.; Sardoč Ž; Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.; Obradović H; Laboratory for Experimental Hematology and Stem Cells, Institute for Medical Research, University of Belgrade, Belgrade, Serbia.; Mojsilović S; Laboratory for Experimental Hematology and Stem Cells, Institute for Medical Research, University of Belgrade, Belgrade, Serbia.; Taskovska M; Department of Urology, University Medical Centre Ljubljana, Ljubljana, Slovenia.; Chair of Surgery, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.; Smrkolj T; Department of Urology, University Medical Centre Ljubljana, Ljubljana, Slovenia.; Chair of Surgery, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.; Kreft ME; Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. |
| Source: | Frontiers in bioengineering and biotechnology [Front Bioeng Biotechnol] 2021 Jun 25; Vol. 9, pp. 690358. Date of Electronic Publication: 2021 Jun 25 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101632513 Publication Model: eCollection Cited Medium: Print ISSN: 2296-4185 (Print) Linking ISSN: 22964185 NLM ISO Abbreviation: Front Bioeng Biotechnol Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Lausanne : Frontiers Media S.A., [2013]- |
| Abstract: | Despite being among the ten most common cancers with high recurrence rates worldwide, there have been no major breakthroughs in the standard treatment options for bladder cancer in recent years. The use of a human amniotic membrane (hAM) to treat cancer is one of the promising ideas that have emerged in recent years. This study aimed to investigate the anticancer activity of hAM homogenate on 2D and 3D cancer models. We evaluated the effects of hAM homogenates on the human muscle invasive bladder cancer urothelial (T24) cells, papillary cancer urothelial (RT4) cells and normal porcine urothelial (NPU) cells as well as on human mammary gland non-tumorigenic (MCF10a) cells and low-metastatic breast cancer (MCF7) cells. After 24 h, we observed a gradual detachment of cancerous cells from the culture surface, while the hAM homogenate did not affect the normal cells. The most pronounced effect hAM homogenate had on bladder cancer cells; however, the potency of their detachment was dependent on the treatment protocol and the preparation of hAM homogenate. We demonstrated that hAM homogenate significantly decreased the adhesion, growth, and proliferation of human bladder invasive and papillary cancer urothelial cells and did not affect normal urothelial cells even in 7-day treatment. By using light and electron microscopy we showed that hAM homogenate disrupted the architecture of 2D and 3D bladder cancer models. The information provided by our study highlights the detrimental effect of hAM homogenate on bladder cancer cells and strengthens the idea of the potential clinical application of hAM for bladder cancer treatment.; (Copyright © 2021 Janev, Ramuta, Tratnjek, Sardoč, Obradović, Mojsilović, Taskovska, Smrkolj and Kreft.) |
| Competing Interests: | The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| References: | Cancer Cell. 2012 Oct 16;22(4):438-51. (PMID: 23079655); Tissue Eng Part A. 2009 Aug;15(8):1919-1927. (PMID: 19196134); PLoS One. 2015 Sep 11;10(9):e0137878. (PMID: 26361392); Histochem Cell Biol. 2005 Jun;123(4-5):529-39. (PMID: 15868181); Mol Biosyst. 2016 Oct 18;12(11):3266-3279. (PMID: 27527902); Oncotarget. 2018 Jul 10;9(53):30146-30162. (PMID: 30046394); Curr Eye Res. 2000 Mar;20(3):173-7. (PMID: 10694891); Drugs. 2017 Jul;77(10):1077-1089. (PMID: 28493171); Mol Biol Rep. 2012 Jan;39(1):467-73. (PMID: 21556762); Br J Cancer. 2001 Jan;84(2):270-5. (PMID: 11161387); Front Microbiol. 2017 Oct 10;8:1948. (PMID: 29089928); Nat Rev Microbiol. 2015 May;13(5):269-84. (PMID: 25853778); Lancet. 2016 May 7;387(10031):1909-20. (PMID: 26952546); BJU Int. 2013 Jul;112(2):E51-8. (PMID: 23795798); Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1024-7. (PMID: 19797205); Indian J Urol. 2015 Oct-Dec;31(4):289-96. (PMID: 26604439); J Biomed Mater Res A. 2016 Jun;104(6):1332-42. (PMID: 26799369); Lancet Oncol. 2017 Mar;18(3):312-322. (PMID: 28131785); Wound Repair Regen. 2010 Jul-Aug;18(4):368-77. (PMID: 20636551); Cryobiology. 2017 Feb;74:61-67. (PMID: 27956223); Tissue Cell. 2015 Feb;47(1):10-6. (PMID: 25441616); World J Transplant. 2014 Jun 24;4(2):111-21. (PMID: 25032100); Cornea. 2001 Aug;20(6):628-34. (PMID: 11473165); Histochem Cell Biol. 2012 Feb;137(2):177-86. (PMID: 22127649); Int Rev Immunol. 2002 Nov-Dec;21(6):471-95. (PMID: 12650238); J Clin Oncol. 2018 Jun 1;36(16):1579-1587. (PMID: 29590008); CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338); J Funct Biomater. 2018 Jan 08;9(1):. (PMID: 29316701); J Tissue Eng Regen Med. 2016 Jul;10(7):613-22. (PMID: 26174407); Placenta. 2017 Nov;59:124-130. (PMID: 28693892); Histochem Cell Biol. 2015 Jan;143(1):95-107. (PMID: 25161121); Am J Obstet Gynecol. 1997 Apr;176(4):915-21. (PMID: 9125621); Oncol Rep. 2000 Jan-Feb;7(1):13-6. (PMID: 10601583); CA Cancer J Clin. 2020 Sep;70(5):404-423. (PMID: 32767764); BMC Complement Altern Med. 2019 Jun 3;19(1):115. (PMID: 31159783); Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. (PMID: 16442208); Cell Tissue Res. 2016 Mar;363(3):599-608. (PMID: 26846225); Semin Cancer Biol. 2015 Dec;35 Suppl:S25-S54. (PMID: 25892662); Biomedicines. 2021 Feb 20;9(2):. (PMID: 33672670); Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1539-46. (PMID: 11381058); Cancer Treat Rev. 2017 Jan;52:48-57. (PMID: 27889637); J Cell Physiol. 1999 Jun;179(3):325-35. (PMID: 10228951); Eur J Cancer. 2016 Feb;54:18-26. (PMID: 26707593); Cornea. 2006 May;25(4):428-31. (PMID: 16670480); Tissue Eng Part A. 2020 Nov;26(21-22):1128-1137. (PMID: 32486914); Oncol Lett. 2017 Nov;14(5):5513-5518. (PMID: 29113179); Indian J Ophthalmol. 2019 Apr;67(4):472-475. (PMID: 30900576); World J Urol. 2009 Jun;27(3):295-300. (PMID: 19271220); Pathol Oncol Res. 2016 Oct;22(4):689-97. (PMID: 26965246); Cornea. 2000 May;19(3):348-52. (PMID: 10832697); Biomed Mater Eng. 2020;31(1):1-17. (PMID: 32144968); Curr Eye Res. 2007 Jul-Aug;32(7-8):611-6. (PMID: 17852184); Ann Oncol. 2019 Jun 1;30(6):970-976. (PMID: 31050707); Stem Cells. 2008 Feb;26(2):300-11. (PMID: 17975221); Front Microbiol. 2020 Mar 24;11:469. (PMID: 32265889); Int J Cell Biol. 2012;2012:676731. (PMID: 22505933); Transl Androl Urol. 2019 Mar;8(Suppl 1):S116-S118. (PMID: 31143685); Int J Ophthalmol. 2015 Feb 18;8(1):29-34. (PMID: 25709903); Placenta. 2013 Apr;34(4):340-5. (PMID: 23465536); Front Bioeng Biotechnol. 2020 Nov 09;8:554530. (PMID: 33240862); Nat Rev Clin Oncol. 2017 Apr;14(4):221-234. (PMID: 27874062); Sci Rep. 2017 Oct 20;7(1):13722. (PMID: 29057887); Cryobiology. 2013 Dec;67(3):293-8. (PMID: 23988559); Cell Transplant. 2020 Jan-Dec;29:963689720946668. (PMID: 32841052); Lancet. 2017 Jan 7;389(10064):67-76. (PMID: 27939400); Int J Oncol. 2017 Nov;51(5):1405-1414. (PMID: 29048644); N Engl J Med. 2017 Mar 16;376(11):1015-1026. (PMID: 28212060); Stem Cells Transl Med. 2016 Nov;5(11):1473-1484. (PMID: 27405780); JAMA Oncol. 2017 Sep 14;3(9):e172411. (PMID: 28817753); Cell Transplant. 2018 Jan;27(1):31-44. (PMID: 29562786); J Cell Mol Med. 2012 Sep;16(9):2208-18. (PMID: 22260183); Nat Rev Dis Primers. 2017 Apr 13;3:17022. (PMID: 28406148); Nature. 2014 Nov 27;515(7528):558-62. (PMID: 25428503); Sci Rep. 2019 Oct 2;9(1):14193. (PMID: 31578445); Eur Urol. 2005 Aug;48(2):189-199; discussion 199-201. (PMID: 15939530); J Clin Oncol. 2017 Jul 1;35(19):2117-2124. (PMID: 28375787); CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593); Med Oncol. 2015 Dec;32(12):257. (PMID: 26507652); Cancer Sci. 2020 Jul;111(7):2423-2430. (PMID: 32350965); Tissue Eng Part C Methods. 2014 Apr;20(4):317-27. (PMID: 23947657); Cytotherapy. 2014 Jan;16(1):33-40. (PMID: 24113429); Cornea. 2017 May;36(5):594-599. (PMID: 28257385); Nat Rev Cancer. 2015 Jan;15(1):25-41. (PMID: 25533674); Cell Transplant. 2016 Dec 13;25(12):2245-2257. (PMID: 27480080); Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6. (PMID: 15939524); Nat Rev Cancer. 2011 Jul 07;11(8):558-72. (PMID: 21734724); Eur Cell Mater. 2008 Apr 29;15:88-99. (PMID: 18446690); Bosn J Basic Med Sci. 2019 Feb 12;19(1):86-93. (PMID: 30579325); Anticancer Res. 2013 Dec;33(12):5235-42. (PMID: 24324055); Front Bioeng Biotechnol. 2015 Oct 19;3:162. (PMID: 26539433); J Ocul Pharmacol Ther. 2011 Aug;27(4):323-6. (PMID: 21702686); Int J Ophthalmol. 2012;5(5):555-61. (PMID: 23166864); Infect Drug Resist. 2019 Oct 29;12:3365-3375. (PMID: 31754306); Nat Rev Urol. 2018 Oct;15(10):615-625. (PMID: 29991725); J Membr Biol. 2014 Apr;247(4):357-60. (PMID: 24577414); Int J Oncol. 2012 Jun;40(6):2022-8. (PMID: 22344679) |
| Contributed Indexing: | Keywords: 2D and 3D in vitro models; cancer; cell cycle; light and electron microscopy; proliferation; urothelium |
| Entry Date(s): | Date Created: 20210712 Latest Revision: 20210713 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC8267883 |
| DOI: | 10.3389/fbioe.2021.690358 |
| PMID: | 34249888 |
| Database: | MEDLINE |
Journal Article